Navigation Links
Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
Date:12/8/2011

NEW HAVEN, Conn., Dec. 8, 2011 /PRNewswire/ -- Cenestra Health announces that the U.S. Patent and Trademark Office (the "USPTO") has issued a new U.S. patent, No. 8,071,646 (the "'646 patent"), that protects and provides Cenestra with exclusivity for highly pure formulations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in ratios ranging from about 3.5:1 to about 5:1.  The '646 patent provides exclusivity for these EPA:DHA ratios in compositions with > 84% omega-3s as the active ingredient. The '646 patent also provides exclusive rights to a number of uses for these superior EPA:DHA ratios.

While Cenestra's previously awarded U.S. patent No. 7,652,068 secured Cenestra's intellectual property on a composition of highly pure ethyl ester forms omega-3 formulations in EPA:DHA ratios of 4.1:1, the '646 patent greatly broadens the opportunity to develop highly unique and best in class EPA:DHA prescription products.  Both patents place Cenestra in a unique position to have therapeutically superior, patent protected products for treatment of diseases such as cardiovascular disease and depression.

"We are pleased that the USPTO recognized the novelty of these specific ratios of EPA to DHA that Cenestra discovered.  Cenestra's research shows that there are clearly superior ratios and dosages of these bioactive lipids for specified applications.  We hope to bring Cenestra's innovative products to patients afflicted with the illnesses that these specific ratios of omega-3s are optimized to treat," said Louis Sanfilippo, M.D., Assistant Clinical Professor at Yale School of Medicine and Managing Director of Cenestra Health.

"We believe that with the granting of the '646 patent, Cenestra finds itself in the unique position as the only high purity omega-3 company with straight-forward composition patents with long patent life remaining.  We believe this will allow Cenestra the ability to garner considerable investment in product development, and sales and marketing.  From the data Cenestra has generated to date, we expect the products developed under the Cenestra patents will confer superior efficacy to those currently on the market or announced to be in development," stated Dr. Sanfilippo. 

About Cenestra, LLC (D/B/A Cenestra Health)

Cenestra Health is a privately-held and unleveraged biopharmaceutical company based in New Haven, Connecticut. Cenestra Health was founded in 2005 to formulate, develop and market "best-in-class" proprietary natural products with applications in the OTC, medical food and pharmaceutical markets. Cenestra Health is focused on the clinical development of its late stage clinical drug candidates for the treatment of dyslipidemias and central nervous system disorders. Cenestra Health is planning to initiate Phase 3 registrational trials in early 2012.

About Omega-3 Essential Fatty Acids

Omega-3 fatty acids are considered "essential" fatty acids (EFAs) as they are necessary to human health but cannot be produced by the body. The two major health promoting omega-3 polyunsaturated fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA have been shown to promote good physical and emotional health, reduce the risk of cardiovascular disease, and exert powerful anti-inflammatory effects. Omega-3 prescriptions in the United States alone accounted for over $1 billion dollars in sales in 2010.

Statements made in this press release should not to be construed as making any specific claim or claims in the diagnosis, prevention or treatment of any disease or disorder but  may relate to historical facts and information that reflect forward looking statements based on Cenestra Health's intellectual property and scientific data.    

  
Investor Contact:  Louis Sanfilippo, M.D., Managing Director
Email: investor.relations@cenestrahealth.com
Telephone: 203-362-8919
Website: www.cenestrahealth.com

US Patent No. 7,652,068/Omega-3 Fatty Acid Formulations
US Patent No. 8,071,646/Omega-3 Fatty Acid Formulations


'/>"/>
SOURCE Cenestra Health
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery
4. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
5. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
6. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
7. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
8. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
9. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
10. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
11. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):